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The subject of nanomedicine has seen a surge in research activity over the past de-
cade, with nanofibers being a particularly active field. Nanofibers are solid, dry fibers
with nanometer diameters, made of various polymers, whereas electrospinning is a ver-
satile, simple, elegant, reproducible, continuous and scalable technology for their prepa-
ration. Nanofibers are a unique class of materials in the biomedical field, since they pro-
vide a biomimetic environment on the nanometer scale, a three-dimensional architecture
with the desired surface properties on the micrometer scale, combined with mechanical
strength and physiological acceptability on the macro scale. In particular, their ability to
imitate the fibrillar elements of a natural extracellular matrix in a very realistic way is
crucial. In this paper we introduce the fundamental aspects of the electrospinning process
and the properties of nanofibers, as well as highlighting the enormous potential of
nanofibers as drug-delivery systems and tissue scaffolds.
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Introduction
In the past decade nanomedicine has experi-
enced an unprecedented rate of advancement, with
nanofibers being a particularly active field, due to
their enormous potential in biomedicine. A biblio-
metric analysis of scientific publications in the “Web
of Science” database clearly shows the tremendous
interest in polymeric nanofibers, with the number of
publications rising from just 100 articles in 2000 to
more than 2300 in 2011, with drug delivery being
the largest research field1. Moreover, it is estimated
that the global market for nanofiber products will be
worth $176 million in 2012. This market is forecast
to grow at a compound annual rate of 34 %, and this
despite the fact that there are just 50 companies in
the world producing nanofibers2.
Nanofibers are solid fibers with several re-
markable nanoscale features, among them is a very
large ratio of surface area to mass, a porous struc-
ture, and a theoretically unlimited length, together
with a better mechanical performance and flexibility
than any other form of the same material (Fig.1)3,4.
They are a unique class of materials in the biomedi-
cal field since they provide a biomimetic environ-
ment on the nanometer scale, a three-dimensional
architecture with the desired surface properties on
the micrometer scale, combined with mechanical
strength and physiological acceptability on the
macro scale.
Of the various processing methods available,
nanofibers are most often prepared by electrospinning.
Compared with other fabrication techniques, such as
drawing, template synthesis and phase separation,
electrospinning is a simple, elegant, reproducible, con-
tinuous and scalable technology with the ability to pro-
duce nanofibers from a wide variety of polymers 5.
The aim of this paper is to describe the funda-
mental aspects of the electrospinning process and
the properties of nanofibers as well as to show the
tremendous potential of nanofibers for applications
in the biomedical field. In particular, the use of
nanofibers in drug-delivery systems and tissue scaf-
folds is highlighted. In this paper we discuss current
research and future challenges.
Electrospinning process
Mechanism of the electrospinning process
Electrospinning is a process for preparing
nanofibers from a polymer solution by the applica-
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F i g . 1 – Polymeric nanofibers on an aluminum collector as
seen by the naked eye and a magnified image of the same sam-
ple under a scanning electron microscope.
tion of a high voltage that induces the formation of
a thin liquid jet3. A standard electrospinning system
is simple in terms of equipment; however, the
physics governing the process is extremely com-
plex. In a standard system, a polymer dissolved in
the proper solvent is put into a syringe fitted with a
metal needle and set on a syringe pump, which pro-
duces a constant flow rate. At a low voltage the
polymer solution drips from the needle, but when
the applied voltage is high enough, it causes the
formation of a cone (the so-called Taylor cone) and
from the tip of this cone a charged fluid jet is
ejected and accelerated towards a grounded collec-
tor (Fig. 2). The jet is continuously stretched and
whipped, which means its diameter is reduced from
several hundred micrometers to as little as tens of
nanometers. Simultaneously, the solvent evaporates
and dry nanofibers are deposited on the collector.
Optimum conditions cause the formation of smooth
nanofibers (Fig. 2A), whereas inappropriate param-
eters lead to a bead-on-string morphology as a re-
sult of the incomplete stretching of the polymer
chains due to an unsuitable proportion of electro-
static forces during the nanofibers’ formation (Fig.
2B)4.
The success of the electrospinning process and
the morphology of the obtained nanofibers depend
on many different, but interrelated, parameters.
Clear evidence for this is seen in Fig. 3, which
shows significant changing of the parameters of
PVA solutions when varying the concentration of
the polymer 6. It is clear that the interdependence of
the parameters complicates the nanofiber design;
however, on the other side minor changes of the pa-
rameters results in the formation of an electrospun
product with the desired morphology and topogra-
phy. Nanofibers have already been successfully pre-
pared from more than 200 natural and synthetic
polymers; nevertheless, the applicability of electro-
spinning is not easily transferable between various
polymer solutions, which means that for each com-
bination of polymer and solvent the appropriate pa-
rameters have to be determined individually4.
Control of the nanofiber’s diameter
and morphology
The parameters affecting the morphology of
the obtained nanofibers can be divided into the so-
lution, process and environmental conditions. In
terms of the solution parameters, the solution vis-
cosity, surface tension and conductivity are the
most determining, while among the process param-
eters the most decisive are the applied voltage, the
feed rate and the distance to the collector4,7,8. Al-
though it is well known that the previously men-
tioned groups of parameters have a predominant in-
fluence on the nanofibers’ formation and morphol-
ogy, the effect of environmental conditions (tem-
perature and humidity) is not negligible. In the text
below some selected parameters are briefly de-
scribed and the effects of all the parameters on the
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F i g . 2 – A schematic illustration of the basic principles of
the electrospinning process. Representative figures taken with a
scanning electron microscope showing two distinctive morpho-
logies of the obtained nanofibers: (A) smooth nanofibers, (B)
bead-on-string morphology.
F i g . 3 – Zero-shear viscosity, conductivity and surface ten-
sion in relation to the concentration of PVA 6
nanofibers’ morphology are schematically pre-
sented in Table 1.
The fiber diameter tends to increase with an in-
creasing polymer concentration and viscosity, but
decreases with an increasing conductivity, while
no strong correlation between the surface tension
and the nanofiber’s morphology has been estab-
lished9–11. However, the solution’s surface tension
determines the threshold voltage needed for the
electrospinning process to occur, since the sur-
face-tension forces have to be overcome by the
electrostatic forces for the formation of a jet7.
Increasing the applied voltage – as the most
important process parameter – generally leads to a
smaller fiber diameter due to the stronger electro-
static forces; however, it can also cause an in-
creased mass flow, leading to a thicker fiber12. The
distance between the needle and the collector deter-
mines the strength of the electric field and together
with the applied voltage governs the stretching of
the polymer jet. The distance should be sufficient to
allow the evaporation of the solvent. In addition,
the solution feed rate should ensure the continuous
formation of the Taylor cone, even though some of
the solution is carried away by the jet24. The nano-
fibers that are formed can be oriented randomly or
aligned on the collector, whereas the arrangement is
mainly a result of the type of collector. The fibers
collected on a planar aluminum foil are usually ran-
domly oriented, while the usage of a rotary drum or
patterned electrodes enables the formation of aligned
nanofibers (Fig. 4)21,25.
Progress in electrospinning techniques resulted
in the development of new methods for the pre-
paration of nanofibers, enabling the mass produc-
tion and formation of various nanofibrillar struc-
tures21,26–28. An example of the latter that has gained
wide popularity is coaxial electrospinning, where
two solutions are coaxially and simultaneously
electrospun through different feeding capillary
channels in one needle to generate nanofibers with
a core-shell structure3,24.
Biocompatible polymers
The selection of a material plays a pivotal role
in the design of nanofibers for biomedical applica-
tions. The ideal biomaterial should be biocompatible,
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T a b l e 1
Solution parameter Effect on nanofiber morphology Ref.
• Concentration Increase in concentration leads to increase in fiber diameter. 4,6,7
• Viscosity Increasing viscosity leads to thicker and beadless nanofibers. Too high viscosity
causes generation of beads.
4,7,12
• Surface tension No conclusive correlation has been established between the surface tension
and the nanofiber morphology.
9,10,11
• Conductivity Increase in conductivity leads to thinner nanofibers. 12–15
• Molecular weight of polymer Increase in polymer molecular weight leads to formation of a nanofiber
with fewer beads.
9,16,17




Sufficient dielectric constant of the solvent is needed for successful electrospinning. 4,15
Process parameter
• Flow rate Lower flow rate results in thinner nanofibers. Too high flow rate causes the
generation of beads.
19,20
• Applied voltage Thinner fiber with higher applied voltage. 4,5,12
• Needle tip to collector distance Minimum distance required to obtain dry nanofibers. Generation of beads when
the distance is too small or too large.
4,9
• Geometry of collector




• Humidity Lower humidity enables higher flow rate and the generation of beads is reduced. 22,23
• Temperature A thinner nanofibers are obtained when the temperature is higher. 23
biodegradable, nontoxic, hydrophilic and with the
proper mechanical strength29. In theory, the choice
of the polymer for electrospinning is not limited,
providing the polymer allows the preparation of a
solution or a melt with the proper characteristics4.
Up to now many different polymers have been
electrospun into nanofibers and can be broadly clas-
sified as either synthetically or naturally derived29.
Among the synthetic ones the most commonly used
are poly(vinyl alcohol) (PVA), poly(ethylene oxide)
(PEO) and biodegradable aliphatic polyesters, such
as poly(lactic acid) (PLA), poly(lactic-co-glycolic
acid) (PLGA), poly(caprolactone) (PCL), while
chitosan, alginate, collagen, gelatin, hyaluronic acid
and silk are examples of frequently used natural
polymers5,30,31. The key biological, mechanical and
physicochemical properties of the commonly used
polymers are presented in Fig. 5.
Synthetic materials are strong, cheap, reliable,
often easily electrospinnable and exert physico-
chemical characteristics that can be controlled
through the production process. However, they lack
cell-recognition sites, causing poor affinity for cell
attachment. On the other hand, natural polymers are
preferred due to their similarity with the macro-
molecular substances present in the human body23.
Therefore, the biological environment recognizes
and favorably interacts with the natural polymers.
The preparation of nanofibers from natural poly-
mers is challenging due to their polyelectrolyte na-
ture and their high viscosity at low concentrations.
Thus, natural polymers are often blended with syn-
thetic polymers, which represent a spinnable carrier
and enable the formation of nanofibers12. Impor-
tantly, the nanofibers prepared from polymer blends
retain the biological functionability of the natural
polymer as well as the mechanical strength and du-
rability of the synthetic component32. Using this
approach we have successfully prepared nanofibers
from chitosan and alginate with the addition of
PEO or PVA. However, the research was mainly fo-
cused on chitosan, due to its outstanding properties,
such as biocompatibility, biodegradability, safety,
hydrophilicity, the ability to suppress an inflamma-
tion response during healing and antimicrobial ac-
tivity, and its enormous potential as an effective
biomaterial for drug-delivery applications, wound
dressings and tissue substitutes. Our results have
shown that the morphology of nanofibers obtained
from chitosan/PEO solutions depends strongly on
the solution composition, since significant changes
in the product morphology were observed, when
the amount of chitosan in the polymer blend was
decreased12. Recent results have also indicated that
the role of humidity in the electrospinning process
was underestimated in previous studies, since the
success of the process can be significantly im-
proved only by lowering the humidity22.
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F i g . 4 – Representative images of (A) randomly ori-
ented and (B) aligned nanofibers under a
scanning electron microscope. Adapted
with permission from25.
F i g . 5 – Biological, mechanical and physicochemical prop-
erties of commonly used polymers. (PGA – poly(glycolic acid),
PLA – poly(lactic acid), PLGA – poly(lactic-co-gylcolic acid),
PCL – poly(caprolactone), PVA – poly (vinyl alcohol), PEO –
poly (ethylene oxide).
The selection of an optimal solvent for each
polymer or polymer blend is fundamental to the
success of the electrospinning. Solvent selection is
pivotal in determining the critical minimum solu-
tion concentration to allow the electrospinning as
well as contributing to the solution surface tension
and conductivity, thereby affecting the solution’s
spinnability and the morphology of the electrospun
nanofibres33. Frequently used solvents for nanofiber
preparation are tetrahydrofuran, dimethylforma-
mide, chloroform, acetic acid, acetone, ethanol,
2,2,2–trifluoroethanol and distilled water5. Distilled
water is a favorable solvent when nanofibers are in-
tended for biomedical applications, since solvent
residues in the formulated nanofibers do not lead to
any safety concerns. Polymers are often not com-
pletely soluble in water; therefore, the addition of
co-solvents in a relatively small proportion is nec-
essary. For example, chitosan/PEO nanofibers can
be successfully prepared from acidic aqueous solu-
tions containing 2 % acetic acid12. Moreover, a mix-
ture of solvents is not only used for the needs of
solubility, but also to accelerate the solvent’s evap-
oration in the electrospinning process. The addition
of a volatile, usually organic, solvent increases the
solvent evaporation rate and, therefore, decreases
the necessary needle-to-collector distance in electro-
spinning. Solvent volatility also affects the fiber po-
rosity, being higher when the solvent evaporates
quickly3. Our results showed that the addition of an
organic solvent is only beneficial in the case when
the polymer is completely soluble in the solvent
mixture4.
The addition of surfactants and salts to the
polymer solutions is another well-established prac-
tice to achieve spinnability of natural and semi-syn-
thetic polymers, improve the reproducibility of the
electrospinning process or transform the product
morphology from beads to fibers4,13. For this
purpose various salts and surfactants can be ap-
plied9,10,12,14,15. In one of our studies the effects of
Tween 80 and NaCl on the electrospinning of a
hydroxylethyl cellulose solution were examined.
Both supplements were chosen due to their safety
and widespread use in several pharmaceutical and
cosmetic products. The addition of Tween 80
lowered the surface tension of the solution, which
resulted in the elongation of the beads into fibers,
an increase in the fiber diameter and an improved
process efficacy. The addition of the salt sig-
nificantly increased the conductivity of the polymer
solution, resulting in a reduced bead formation and
a larger fiber diameter. It was shown that the addi-
tion of a surfactant improved the nanofiber mor-
phology to a much greater extent than the addition
of salt4.
Drug loading
Active substances can be incorporated inside
the nanofibers, physically adsorbed or chemically
bound to the surface (Fig. 6)34. However, knowl-
edge of the drug’s behavior during its incorporation
in the nanofibers and its subsequent release from
the nanofibers is much more limited, compared to
the knowledge available for drug incorporation and
release from, for example, solid lipid nanoparticles.
The loading of many different drugs and their local-
ization in the lipid matrix have been systematically
investigated34–36. The results showed that the drug
incorporation, localization and release depend on
the physicochemical properties of the drug and the
carrier matrix. Therefore, it is also expected that for
nanofibers the loading mechanism will be governed
by the drug solubility in the polymer solution and
the drug–polymer interactions in the solid state.
Of the various loading possibilities, physical
entrapment is currently the most widespread, since
the drug in the nanofibers is protected against unfa-
vorable environmental conditions and it offers good
control over the drug’s release. A typically ob-
served release profile from such nanofibers exhibits
an initial burst effect followed by an almost linear,
sustained release24. Furthermore, the preparation of
core-shell nanofibers provides a drug-reservoir sys-
tem with a shell barrier protecting the incorporated
drug and controlling the drug diffusion rate. The
burst effect from such nanofibers is small and the
entire release profile is more sustained31,37.
The incorporation of a drug in nanofibers, ei-
ther in the form of a matrix or as a core-shell sys-
tem, is relatively easy to perform, since the drug is
simply dissolved in the polymer solution prior to
electrospinning. The formation of an amorphous
drug, which shows a higher solubility with respect
to the crystalline form38,39, is favored, due to a
very limited time being available for the drug’s
recrystallization during the electrospinning pro-
cess40–42. Furthermore, a reasonable question can be
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F i g . 6 – Scheme presenting the possibilities of drug load-
ing in/on nanofibers
raised concerning the preservation of the chemical
and biological integrity of the incorporated drug
due to the application of a high voltage during
the electrospinning. Various studies using H-NMR,
DSC, X-ray and IR spectroscopy have proven that
the electrospinning process does not affect the
structural integrity of the incorporated drug3,31,40,43.
The physical adsorption of a drug on the sur-
face of the preformed nanofibers is achieved by
dipping the nanofibers into a solution of the drug,
which associates with the nanofibrillar surface via
electrostatic interactions36. However, this technique
is seldom used due to poor control over the drug’s
release and an undesirable competitive displace-
ment of the drug with the components of biological
fluids.
The third approach to drug loading is the cova-
lent immobilization of the drug on the nanofibrillar
surface via the formation of chemical bonds. The
latter is predominately used for the modification of
the surface properties of nanofibers, since the tech-
nique is technically complex. However, there are
some reports dealing with this approach for the de-
livery of active substances. The drug is released af-
ter the enzymatic or environmental degradation of
the chemical bond37.
Use of nanofibers in biomedicine
Electrospun nanofibers as 2D and 3D scaffolds
Tissue engineering is an interdisciplinary field
with the fundamental aim being to utilize the
body’s natural biological response to achieve suc-
cessful tissue regeneration. Currently, two strategies
have emerged as the most promising tissue-engi-
neering approaches: one being the implantation of
pre-cultured cells and a synthetic scaffold at the site
of a tissue defect and the other being the application
of an acellular scaffold at the site of the tissue de-
fect immediately after the injury37. There has been
increased interest in the latter approach, also due to
the progress in the area of nanofibers. The underly-
ing rationale for the use of nanofibrillar tissue scaf-
folds is a biomimetic approach. Electrospun nano-
fibers can mimic the physical structure of the major
constructive elements of the native extracellular
matrix (ECM) in terms of shape, size and mechani-
cal properties. Furthermore, the fiber can also re-
semble the tissue biology, since almost all the tis-
sues are constructed and hierarchically organized
from fibrous structural elements23. All this suggests
that such scaffolds could promote cell attachment,
proliferation and differentiation. Tissue damaged as
a result of an injury or disease is often accompanied
by the loss of the ECM, which has to be regener-
ated in the healing process. In some cases, such as
chronic wounds, the reconstruction of the natural
ECM is disrupted, due to the imbalance between
the regeneration and degeneration processes, lead-
ing to delayed or even prevented healing. There-
fore, it is reasonable to expect that the application
of ECM analogues will help with the recovery44,45.
The preparation of nanofibers for tissue regen-
eration can be adapted for a specific place in the
body, because of the wide range of biocompatible
polymers available and the flexibility of the electro-
spinning process. For example, studies have shown
that nanofibers used for artery-wall reconstruction
should be applied in a sufficiently thick layer to
withstand the pulsating blood flow. Aligned nano-
fibers resemble more closely the structure of the
vasculature and the nerves than randomly oriented
fibers23,46. The nanofibers for application in bone
remodeling usually contain hydroxapatite, since the
inorganic component improves the mechanical
properties of the scaffold, makes it comparable to
the natural bone and improves its osteoconductivity
and osteointegration21.
Various independent studies have proven the
influence of nanofibers on the morphology of dif-
ferent cells47–51. Our results indicated that cells
grown on nanofibers have an altered morphology in
comparison to cells grown on a flat glass surface.
Furthermore, the thickness and orientation of the
nanofibers also affect the cell behavior. While cells
grown on a randomly oriented, relatively thick,
nanofibrillar support adopted a more rounded mor-
phology, the others grown on aligned nanofibers
had a distinctly elongated morphology and an im-
proved mobility. The orientation of the nanofibers
can govern the cell shape and the direction of the
cell migration. Additionally, it was shown that the
cell attachment to the nanofibers is slightly delayed
compared to the attachment to a glass surface; how-
ever, it is much stronger due to the improved focal
adhesion and the physical entrapment of cells in the
electrospun scaffold. The cells grown on nanofibers
exert an increased metabolic activity, which clearly
indicates that the nanosized elements of the artifi-
cial ECM play a crucial role in the stimulation of
the cell proliferation52 .
There is an increasing demand for bioactive
scaffolds that can, besides physical support, provide
a local release of incorporated biomolecules, which
stimulate the regeneration of the surrounding tissue.
The ECM is much more than just a physical support
in the tissue, it represents a substrate with expressed
specific ligands for cell adhesion, enables and ori-
ents the cell migration and regulates the cell growth
and functions through the release of different bio-
active factors. As a result, various growth factors as
well as glucosaminoglycans have been incorporated
into and on the surface of the nanofibers to improve
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the tissue-regeneration properties37. However, addi-
tional investigations are required.
Drug delivery
Polymeric nanofibers have been used as carri-
ers for the local delivery of therapeutic agents to
target sites in the body24. The first report about
nanofibers as drug-delivery systems was published
by Kenawy et al., who incorporated tetracycline hy-
drochloride into nanofibers prepared from PLA or
poly(ethylene-co-vinyl acetate) or from a blend of
both polymers in a ratio 50:50 (w/w). The release
profiles showed a relatively smooth release over 5
days, with a greater total percentage released than
from the corresponding films, while eliminating the
initial burst effect53. Later studies investigated the
incorporation of various types of active substances,
such as antibiotics46,54, antiseptics55, non-steroidal
anti-inflammatory drugs56,57, anti-cancer drugs47,58,59
as well as biomolecules such as proteins5,60,61 and
nucleic acids62.
Taepaiboon et al. reported the development of
electrospun PVA nanofibers for the transdermal
drug delivery of four, non-steroidal, anti-inflamma-
tory drugs differing in aqueous solubility, i.e., so-
dium salicylate, diclofenac sodium, naproxen and
indomethacin. The molecular weight of a drug has
an important effect on both the rate and the total
amount of drug released, with both decreasing for
an increasing molecular weight of the drug. The
drug-loaded electrospun PVA mats exhibited better
controlled release characteristics of the model drugs
than the drug-loaded films56.
One of the largest areas in drug-delivery re-
search is the targeted and controlled delivery of
anti-cancer drugs. Xie and Wang developed
PLGA-based nanofibers as implants for the sus-
tained delivery of the anti-cancer drug paclitaxel to
treat C6 glioma cells in vitro. The results showed
the sustained release of paclitaxel over a period of
more than 60 days, while the citotoxicity was com-
parable to the commercial paclitaxel formulation
known as Taxol® 47. Xu et al. incorporated two dif-
ferent anti-cancer drugs, i.e., hydrophilic doxorub-
icin hydrochloride and lipophilic paclitaxel, in
PLA-PEO nanofibers63. The results indicated that
the release behavior of both drugs correlated with
their aqueous solubility and distribution in the fi-
bers. Therefore, a faster release was observed for
the more soluble hydrophilic doxorubicin hydro-
chloride. An in vitro cytotoxicity assay indicated
the higher inhibition and apoptosis of the cells in
the case of a dual drug combination compared to
the effectiveness of a single-drug-loaded system,
which suggests promise for multi-drug delivery and
successful combined therapies.
Nowadays, more and more active substances
belong to the class of proteins, and nanofibers can
also be successfully applied for the delivery of such
biomolecules. Since proteins are sensitive mole-
cules, special attention has to be given to the pres-
ervation of their native structure in the electrospin-
ning process. Therefore, coaxial electrospinning is
frequently used. Chew et al. investigated the feasi-
bility of encapsulating the human -nerve growth
factor in copolymer nanofibers from PCL and
ethylene phosphate and proved its sustained release
for at least 3 months 49. Human epidermal growth
factor (EGF) was immobilized on the PCL and
PCL-PEO electrospun nanofibers for the treatment
of diabetic ulcers by Choi et al48. The EGF nano-
fibers exerted superior in vivo wound-healing prop-
erties compared to the control groups or the group
treated with the EGF solution. Furthermore, Yang et
al. indicated that wounds, created in the dorsal area
of diabetic rats, treated with nanofibers incorporat-
ing basic fibroblast growth factor, showed a signifi-
cantly faster wound-recovery rate. The complete
re-epithelialization and phenomenon of mature cap-
illary vessels was observed 2 weeks after the onset
of the treatment50. The above results demonstrate
the unique potential of nanofibers to rapidly restore
the structural and functional properties of wounded
skin in patients with diabetes mellitus.
Another step forward was the incorporation of
live cells into fibers with a micrometer diameter.
Townsend-Nicolson and Jayasinghe successfully
encapsulated cells into poly(dimethyl siloxan) fi-
bers using coaxial electrospinning, whereas the cell
viability stayed high throughout the electrospinning
process and no change in the cell morphology was
observed64. On the other hand, Canbolat et al.
proved that a large proportion of cells embedded in
nanofibers were incapacitated during the electro-
spinning when a single needle was used. The results
indicated that the underlying reasons are fiber
stretching and dehydration in the dry fiber65.
To sum up, all the aforementioned results
clearly indicate the suitability and uniqueness of
nanofibers as a delivery system, which does not en-
sure only the desired release profile of the specific
drug, but also provides a biomimetic environment
in the place of application.
Future challanges
Despite the intensive research in the field of
nanofibers a number of unanswered questions still
remain to act as a driving force for further studies.
The largest challenge is a complete understanding
of the electrospinning mechanism. In order to con-
trol the properties, orientation and mass production
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of the nanofibers, it is necessary to understand
quantitatively how electrospinning transforms the
fluid solution through a millimeter-sized needle into
solid fibers having diameters that are four-to-five
orders smaller. The next bottleneck in the electro-
spinning is the process efficiency and repeatability.
Furthermore, the construction of a proper, three-di-
mensional scaffold remains a technological chal-
lenge, while from the point of view of drug delivery
the drug loading has to be increased and the initial
burst release has to be reduced in many cases.
Last but not the least, the future should see a
move towards more in vivo testing, since the major-
ity of work is currently done in vitro, in order to
evaluate the performance of nanofibers in a biologi-
cal environment. Consequently, more animal stud-
ies are needed to fully explore the potential of
nanofibers for clinical applications. A close cooper-
ation between laboratories and clinics may help to
translate this promising technique from lab to bed
and confirm the therapeutic benefit of nanofibers in
regenerative medicine in the near future.
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